AstraZeneca has explored an acquisition of U.S. pharmaceutical rival Bristol Myers Squibb in a deal that could value the combined company at nearly $400 billion. It is unclear whether the talks are ongoing or will result in a transaction.
Such a merger would expand AstraZeneca's presence in the United States, combining two major players with overlapping oncology franchises and complementary pipelines across immunology, cardiovascular, respiratory, renal and metabolic therapies.
AstraZeneca declined to comment. Bristol Myers Squibb could not be reached for comment.
At $400 billion, the deal would rank among the largest in pharmaceutical history. Large-scale mergers in the sector typically target pipeline synergies, cost efficiencies and expanded geographic reach, often driven by patent expirations and pressure to replace eroding revenue streams.
A transaction of this scale would face scrutiny from antitrust regulators in multiple jurisdictions, with reviews focused on market concentration in therapeutic areas where both companies hold significant positions. Approval processes typically extend over many months.
Pharmaceutical consolidation has been a persistent trend over the past decade as companies seek to spread high drug-development costs across a wider revenue base and replenish pipelines ahead of patent cliffs.
